International Support, Vaccinology Unit, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
Am J Public Health. 2013 Aug;103(8):1393-401. doi: 10.2105/AJPH.2012.301075. Epub 2013 Jun 13.
At the beginning of the 1960s, it was clear that a vaccine against measles would soon be available. Although measles was (and remains) a killer disease in the developing world, in the United States and Western Europe this was no longer so. Many parents and many medical practitioners considered measles an inevitable stage of a child's development. Debating the desirability of measles immunization, public health experts reasoned differently. In the United States, introduction of the vaccine fit well with Kennedy's and Johnson's administrations' political commitments. European policymakers proceeded cautiously, concerned about the acceptability of existing vaccination programs. In Sweden and the Netherlands, recent experience in controlling polio led researchers to prefer an inactivated virus vaccine. Although in the early 1970s attempts to develop a sufficiently potent inactivated vaccine were abandoned, we have argued that the debates and initiatives of the time during the vaccine's early history merit reflection in today's era of standardization and global markets.
20 世纪 60 年代初,麻疹疫苗很快就会问世,这一点已经很清楚。虽然麻疹(现在仍然是)发展中国家的一种致命疾病,但在美国和西欧已不再如此。许多父母和医生认为麻疹是儿童发育过程中不可避免的阶段。在讨论麻疹免疫接种的可取性时,公共卫生专家的看法不同。在美国,疫苗的推出与肯尼迪和约翰逊政府的政治承诺非常吻合。欧洲政策制定者行事谨慎,担心现有疫苗接种计划的可接受性。在瑞典和荷兰,控制脊髓灰质炎的最新经验促使研究人员更倾向于使用灭活病毒疫苗。尽管在 20 世纪 70 年代早期,人们曾试图开发出一种足够有效的灭活疫苗,但我们认为,在疫苗的早期历史中,当时的辩论和举措值得在当今标准化和全球市场的时代进行反思。